Financial Performance - TriSalus Life Sciences, Inc. reported a quarterly loss of $0.96 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.17, representing an earnings surprise of -464.71% [1] - The company posted revenues of $11.57 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.79%, and showing an increase from $7.35 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.13 on revenues of $12.88 million, and for the current fiscal year, it is -$0.86 on revenues of $44.69 million [7] Stock Performance - TriSalus Life Sciences, Inc. shares have declined approximately 11.8% since the beginning of the year, contrasting with the S&P 500's gain of 16.5% [3] - The company has not surpassed consensus EPS estimates over the last four quarters, indicating a trend of underperformance [2] Industry Outlook - The Medical - Products industry, to which TriSalus belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of TriSalus may be influenced by the overall outlook of the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]
TriSalus Life Sciences, Inc. (TLSI) Reports Q3 Loss, Tops Revenue Estimates